Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline

Table 1 Comparisons of baseline and follow-up characteristics by Aβ and WMH status

	Aβ- WMH-	Aβ- WMH+	Aβ + WMH-	Aβ + WMH+
	n = 140	n = 39	n = 63	n = 29
Baseline characteristics
Age	61.7 (8.3)^B,C,D	71.3 (7.7)^A,C	66.7 (7.8)^A,B,D	74.1 (5.0)^A,C
Female, n	94 (67)^C	23 (59)	32 (51)^A	16 (55)
Education in years	10.9 (3.1)	11.9 (3.3)	11.1 (3.1)	10.3 (2.9)
Hypertension, n^*	43 (34)	9 (25)	15 (25)	9 (32)
Obesity, n^*	15 (14)	3 (11)	4 (8)	4 (21)
Diabetes, n^*	16 (21)	3 (15)	3 (7)	5 (28)
APOE-ε4 carrier, n^*	33 (51)^B	5 (24)^A,C,D	29 (62)^B	10 (56)^B
Diagnosis MCI, n	70 (50)^D	21 (54)^D	40 (64)	22 (76)^A,B
amnestic MCI (% within MCI group)	40 (57)	15 (71)	27 (68)	17 (77)
non-amnestic MCI (% within MCI group)	30 (43)	6 (29)	13 (33)	5 (23)
CSF Aβ 1–42, pg/ml	973.6 (312.0)^C,D	885.0 (242.0)^C,D	404.3 (102.6)^A,B	419.3 (97.2)^A,B
White matter hyperintensities^†	0.7 (0.5)^B,D	2.3 (0.4)^A,C	0.8 (0.4)^B,D	2.4 (0.5)^A,C
Follow-up characteristics
Follow-up time	2.1 (1.5)	2.2 (1.3)	2.1 (1.2)	2.4 (1.2)
Time to progression to dementia	1.3 (0.5)^B	2.0 (0.7)^A	1.7 (0.7)	2.1 (1.2)
Progression to dementia, n	8 (6)^B,C,D	9 (23)^A	18 (29)^A	11 (38)^A
- AD-type dementia, n	2 (1)^B,C,D	7 (18)^A	18 (29)^A	10 (35)^A
- Vascular dementia, n	0 (0)	2 (5)	0 (0)	1 (3)
- Frontotemporal dementia, n	4 (3)	0 (0)	0 (0)	0 (0)
- Lewy Body dementia, n	1 (1)	0 (0)	0 (0)	0 (0)
- Dementia with unknown etiology, n	1 (1)	0 (0)	0 (0)	0 (0)

Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sample
Abbreviations: Aβ amyloid-beta, AD Alzheimer’s disease, APOE Apolipoprotein E, MCI mild cognitive impairment
^†WMH measured by the Fazekas scale, range 0–3
^Ap < 0.05 compared to Aβ- WMH-
^Bp < 0.05 compared to Aβ- WMH+
^Cp < 0.05 compared to Aβ + WMH-
^Dp < 0.05 compared to Aβ + WMH+

ISSN: 1758-9193